

Online supplementary appendix 1

Excluded References

One were excluded because it recruited less than 10 patients in one of study groups [1], nine were excluded because the same authors published several reports on the same patients, and only the best-quality study was considered [2-10], twenty-two were excluded because they did not allow the calculation of sensitivity or specificity [11-32].

1. Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, Maeda M, Takahashi K, Masuda K, Sakao Y, Hino O. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. *Cancer Sci* 2006; 97(9): 928-932.
2. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Soluble mesothelin-related protein--a blood test for mesothelioma. *Lung Cancer* 2005; 49 Suppl 1: S109-111.
3. Creaney J, Christansen H, Lake R, Musk AB, de Klerk N, Robinson BW. Soluble mesothelin related protein in mesothelioma. *J Thorac Oncol* 2006; 1(2): 172-174.
4. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. *Clin Cancer Res* 2006; 12(2): 447-453.
5. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Gregoire M, Porte H, Copin MC, Lassalle P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. *Clin Cancer Res* 2007; 13(10): 2928-2935.
6. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. *Ann Thorac Surg* 2008; 85(1): 265-272; discussion 272.

7. Grigoriu B, Chahine B, Zerimech F, Gregoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. *Clin Biochem* 2009; 42(10-11): 1046-1050.
8. Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpre P, De Vuyst P, Bosquee L, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. *Chest* 2012; 141(2): 477-484.
9. Canessa PA, Ferro P, Manta C, Sivori M, Franceschini MC, Fedeli F, Roncella S. Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report. *Med Oncol* 2013; 30(3): 649.
10. Creaney J, Dick IM, Segal A, Musk AW, Robinson BW. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. *Lung Cancer*, 2013;82: 491-498.
11. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. *Thorax* 2007; 62(7): 569-576.
12. Weber DG, Taeger D, Pesch B, Kraus T, Bruning T, Johnen G. Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma. *Cancer Biomark* 2007; 3(6): 287-292.
13. Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. *Lung Cancer* 2008; 61(2): 235-243.
14. Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. *Am J Respir Crit Care Med* 2009; 179(10): 950-954.
15. Aleman C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S, de Sevilla TF. Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions. *Med Clin (Barc)* 2009; 133(12): 449-453.
16. Rai AJ, Flores RM, Mathew A, Gonzalez-Espinoza R, Bott M, Ladanyi M, Rusch V, Fleisher M. Soluble mesothelin related peptides (SMRP) and osteopontin as protein

biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. *Clin Chem Lab Med* 2010; 48(2): 271-278.

17. Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. *Cancer Epidemiol Biomarkers Prev* 2010; 19(9): 2238-2246.

18. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leigh N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. *J Clin Oncol* 2010; 28(20): 3316-3322.

19. Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Muller-Lux A, Gross IM, Wiethage T, Weber A, Raithel HJ, Kraus T, Bruning T. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. *Arch Toxicol* 2011; 85(3): 185-192.

20. Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. *Clin Cancer Res* 2011; 17(5): 1181-1189.

21. Nelson HH, Almquist LM, LaRocca JL, Plaza SL, Lambert-Messerlian GM, Sugarbaker DJ, Bueno R, Godleski JJ, Marsit CJ, Christensen BC, Kelsey KT. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma. *Epigenetics* 2011; 6(8): 1029-1034.

22. Imashimizu K, Shiomi K, Maeda M, Aoki N, Igarashi K, Suzuki F, Koizumi M, Suzuki K, Hino O. Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for the early diagnosis of malignant mesothelioma. *Exp Ther Med* 2011; 2(3): 409-411.

23. Hollevoet K, Van Cleemput J, Thimpont J, De Vuyst P, Bosquee L, Nackaerts K, Germonpre P, Vansteelandt S, Kishi Y, Delanghe JR, van Meerbeeck JP. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study. *J Thorac Oncol* 2011; 6(5): 889-895.

24. Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquee L, De Vuyst P, Germonpre P, Kellen E, Legrand C, Kishi Y, Delanghe JR, van Meerbeeck JP. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. *J Thorac Oncol* 2011; 6(11): 1930-1937.
25. Boudville N, Paul R, Robinson BW, Creaney J. Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening. *Lung Cancer* 2011; 73(3): 320-324.
26. Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, Sartini D, Pozzi V, Carbonari D, Bracci M, Pignotti E, Mazzanti P, Sabbatini A, Ranaldi R, Gasparini S, Neuzil J, Tomasetti M. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. *PLoS One* 2011; 6(4): e18232.
27. Park EK, Wilson D, Yates DH. A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels. *Clin Chem Lab Med* 2012; 50(12): 2199-2204.
28. Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma. *Dis Markers* 2012; 32(2): 123-131.
29. Mori T, Tajima K, Hiramata M, Sato T, Kido K, Iwakami S, Sasaki S, Iwase A, Shiomi K, Maeda M, Hino O, Takahashi K. The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma. *J Thorac Dis* 2013; 5(2): 145-148.
30. Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J. Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung Cancer. *J Thorac Oncol* 2013; 8(7): 947-951.
31. Creaney J, Dick IM, Dare H, Demelker Y, Nowak AK, Musk AW, Robinson BW. Does CA125 binding to mesothelin impact the detection of malignant mesothelioma? *Lung Cancer* 2013; 80(1): 39-44.
32. Mundt F, Nilsson G, Arslan S, Csürös K, Hillerdal G, Yildirim H, Metintas M, Dobra K, Hjerpe A. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. *PLoS One* 2013; 8(8): e72030.